NIH accelerates the use of genomics in clinical care

The National Institutes of Health (NIH) is awarding $18.9 million towards research that aims to accelerate the use of genome sequencing in clinical care.

The new awards will generate innovative approaches and best practices to ensure that the effectiveness of genomic medicine can be applied to all individuals and groups, including diverse and underserved populations, and in healthcare settings that extend beyond academic medical centres.

The research is being funded as part of the Clinical Sequencing Evidence-Generating Research (CSER2) Consortium. CSER2 builds upon the Clinical Sequencing Exploratory Research (CSER) Consortium, initiated in 2010 and funded by the National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), both part of NIH. The new grants will support the development of methods needed to integrate genome sequencing into the practice of medicine, improve the discovery and interpretation of genomic variants, and investigate the impact of genome sequencing on healthcare outcomes.

With this new round of funding, CSER2 investigators will continue the effort to generate evidence for the usefulness of genome sequencing in clinical care, but with a focus on diverse and underserved individuals. To that end, NHGRI and NCI have partnered with the National Institute on Minority Health and Health Disparities (NIMHD) to improve processes for recruiting and retaining patients to participate in research from diverse racial and ethnic groups, as well as from currently understudied clinical healthcare settings where genomic medicine could potentially be put into practice.

CSER2 is awarding grants to six clinical sites and one coordinating centre, with the awards planned for a total of four years. CSER2 will also continue to include collaborators such as those from the NHGRI Intramural ClinSeqÒ study. The clinical sites – all with a goal of recruiting at least 60 percent of participants from diverse or underserved settings – will include research that covers geographical areas from the racially diverse populations in Houston, to the underrepresented minority populations in Harlem and the Bronx in New York.

Each project will address additional areas that will be common across CSER2 sites, such as the effectiveness of treatment decisions; patient and familial response to genomic testing; patient-provider-laboratory interactions that influence the use of genome sequencing; and integrating genomic, clinical and healthcare data to build a shared evidence base for clinical decision making.